Damon R Reed

Trials

Studies that name Damon R Reed as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:35 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04616560 · Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  National Cancer Institute (NCI) · recruiting · Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application
  UM1CA228823 · NCI · COG RESEARCH FOUNDATION, LLC · PI Elizabeth Fox · fiscal years 2018 to 2026
  Named on NCT04616560